☆ 4.5 Editorial Material

Metastatic breast cancer patients: The forgotten heroes!

BREAST (2009)

Journal

BREAST

Volume 18, Issue 5, Pages 271-272

Publisher

CHURCHILL LIVINGSTONE

DOI: 10.1016/j.breast.2009.09.001

Keywords

-

Categories

Oncology Obstetrics & Gynecology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Multidisciplinary Sciences

Genomics to select treatment for patients with metastatic breast cancer

Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Herve Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Goncalves, Thomas Bachelot, Ivan Bieche

Summary: Cancer progression is driven by genomic alterations. Genomic profiling can help select effective therapies. A study on HER2-non-overexpressing metastatic breast cancer patients showed that targeted therapies matched to genomic alterations can improve progression-free survival, especially for patients with BRCA1/2 mutations.

NATURE (2022)

Add to Collection

Article Oncology

Technology-based supportive care for metastatic breast cancer patients

Kathryn H. H. Schmitz, Beth Kanski, Brett Gordon, Maxime Caru, Monali Vasakar, Cristina I. I. Truica, Ming Wang, Shawna Doerksen, Abby Lorenzo, Renata Winkels, Ling Qiu, Saeed Abdullah

Summary: The purpose of this study was to test the effectiveness of a virtual assistant called Nurse AMIE in addressing symptoms in metastatic breast cancer patients. In a partial crossover randomized trial, the intervention group received the intervention for 6 months, while the comparison group was unexposed for the first 3 months and then exposed for 3 months. Although there were high levels of acceptability, feasibility, and satisfaction, the intervention did not have statistically significant effects on symptoms, quality of life, or function.

SUPPORTIVE CARE IN CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

The metastatic spread of breast cancer accelerates during sleep

Zoi Diamantopoulou, Francesc Castro-Giner, Fabienne Dominique Schwab, Christiane Foerster, Massimo Saini, Selina Budinjas, Karin Strittmatter, Ilona Krol, Bettina Seifert, Viola Heinzelmann-Schwarz, Christian Kurzeder, Christoph Rochlitz, Marcus Vetter, Walter Paul Weber, Nicola Aceto

Summary: The generation of circulating tumor cells (CTCs) with metastatic ability is concentrated during the rest phase, and CTCs generated during the active phase lack metastatic ability. Mechanistically, the upregulation of mitotic genes during the rest phase enables CTCs' metastasis proficiency. Circadian rhythm hormones such as melatonin, testosterone and glucocorticoids dictate the generation dynamics of CTCs, and insulin promotes tumor cell proliferation in a time-dependent manner.

NATURE (2022)

Add to Collection

Article Oncology

Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients

Mahsa Taskindoust, Samantha M. Thomas, Sarah L. Sammons, Oluwadamilola M. Fayanju, Gayle DiLalla, E. Shelley Hwang, Jennifer K. Plichta

Summary: Advances in therapies have improved overall and cancer-specific survival for metastatic breast cancer patients over time. However, more patients, particularly with limited distant disease or favorable tumor subtypes, are also dying from non-MBC causes.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

How we treat patients with metastatic HER2-positive breast cancer

G. Nader-Marta, D. Martins-Branco, E. de Azambuja

Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.

ESMO OPEN (2022)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutics targeting the metastatic breast cancer bone microenvironment

Claire L. Ihle, Sabrina J. Wright-Hobart, Philip Owens

Summary: The survival rate of breast cancer patients has improved, but metastatic breast cancer still causes high mortality. Metastasis mainly occurs in the bone, and current treatment methods focus on palliative care and slowing down the progression. Recent advances in molecularly targeted agents have made breakthroughs in the treatment of metastatic breast cancer, but immunotherapies have not been fully applied in estrogen receptor-positive tumors. Therapeutic approaches targeting the bone microenvironment of metastatic breast cancer have potential applications in other bone-resident cancers.

PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Oncology

Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer

Jennifer K. Plichta, Samantha M. Thomas, Daniel F. Hayes, Mariana Chavez-MacGregor, Kimberly Allison, Jennifer de los Santos, Amy M. Fowler, Armando E. Giuliano, Priyanka Sharma, Benjamin D. Smith, Elizabeth van Eycken, Stephen B. Edge, Gabriel N. Hortobagyi

Summary: This study developed a staging system for patients with metastatic cancer at the time of initial diagnosis, aimed at improving prognostic estimates. The heterogeneity in outcomes for metastatic breast cancer patients could guide future revisions of staging guidelines for newly diagnosed stage IV disease.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Ippei Fukada, Seiichi Mori, Naomi Hayashi, Mari Hosonaga, Masumi Yamazaki, Xiaofei Wang, Saori Kawai, Lina Inagaki, Yukinori Ozaki, Kokoro Kobayashi, Fumikata Hara, Takayuki Kobayashi, Arisa Ueki, Tomo Osako, Akiko Tonooka, Kengo Takeuchi, Takayuki Ueno, Toshimi Takano, Shinji Ohno, Shunji Takahashi

Summary: Comprehensive cancer genomic profile (CGP) tests are being implemented in Japan under the universal health insurance system. This study evaluated the clinical usefulness of CGP tests for breast cancer patients with metastasis. The results showed that CGP tests can provide actionable gene mutations for personalized treatment strategies, and clinical trial participation may be recommended based on the findings.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

The Forgotten (Invisible) Healthcare Heroes: Experiences of Canadian Medical Laboratory Employees Working During the Pandemic

Basem Gohar, Behdin Nowrouzi-Kia

Summary: This qualitative study aimed to understand the stressors and coping strategies of medical laboratory technologists and assistants working during the COVID-19 pandemic in Ontario, Canada. Results showed consistent stressors and coping methods between the two focus groups, with main themes including staff shortage, being forgotten within the healthcare system, poor work environment, and a resilient and passionate team.

FRONTIERS IN PSYCHIATRY (2022)

Add to Collection

Article Oncology

Cancer treatment-specific medication beliefs among metastatic breast cancer patients: a qualitative study

Victoria K. Marshall, Constance Visovsky, Pooja Advani, Dawn Mussallem, Cindy Tofthagen

Summary: This study explored cancer treatment-specific medication beliefs among women with metastatic breast cancer. The findings revealed that participants generally believed that the benefits of cancer treatment outweighed the risks in the context of metastatic disease. They understood their prognosis and relied on cancer treatment for survival.

SUPPORTIVE CARE IN CANCER (2022)

Add to Collection

Review Medicine, General & Internal

The Innate Immune Microenvironment in Metastatic Breast Cancer

Chiara Tommasi, Benedetta Pellegrino, Anna Diana, Marta Palafox Sancez, Michele Orditura, Mario Scartozzi, Antonino Musolino, Cinzia Solinas

Summary: The immune system plays an important role in neoplastic disease, but the role of innate immunity in cancer development and progression is still not well understood. The tumor microenvironment influences the terminal differentiation of innate immune cells, which can have either a pro-tumor or anti-tumor effect. Macrophages, natural killer cells, monocytes, dendritic cells, and neutrophils, along with elements of the complement system, are the key players of innate immunity in cancer development and evolution.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Metabolic abnormalities and survival among patients with non-metastatic breast cancer

Alexa S. Zimbalist, Bette J. Caan, Wendy Y. Chen, Elizabeth A. Mittendorf, Deborah A. R. Dillon, Charles Quesenberry, Elizabeth M. Cespedes Feliciano

Summary: This population-based cohort study found that elevated fasting glucose and low HDL-C were associated with higher breast cancer-specific mortality, while elevated levels of triglycerides and LDL-C were not associated with breast cancer-specific mortality.

BMC CANCER (2022)

Add to Collection

Review Oncology

The lingering mysteries of metastatic recurrence in breast cancer

Alessandra I. Riggio, Katherine E. Varley, Alana L. Welm

Summary: This review provides an overview of the key factors influencing metastatic recurrence in breast cancer, highlighting critical unanswered questions that need to be addressed.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Decoupling convolution network for characterizing the metastatic lymph nodes of breast cancer patients

Rutong Zeng, Xiang Zhang, Chushan Zheng, Jin-Hong Du, Zixiong Gao, Wei Jun, Jun Shen, Yao Lu

Summary: A new decoupling neural network based quantification method for DECT analysis was presented in this study, showing potential as a noninvasive tool to predict metastasis lymph node status for breast cancer. By introducing spectral convolution and focal loss, the AUC on the test set could be improved by 0.15 and 0.01 separately. The proposed approach demonstrated a considerably better performance compared to baseline approaches, with a test set AUC value of 0.837.

MEDICAL PHYSICS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The mutual determination of self-efficacy to cope with cancer and cancer-related coping over time: a prospective study in women with breast cancer

E. C. Karademas, I Roziner, K. Mazzocco, R. Pat-Horenczyk, B. Sousa, A. J. Oliveira-Maia, G. Stamatakos, F. Cardoso, D. Frasquilho, E. Kolokotroni, R. Lemos, C. Marzorati, J. Mattson, G. Pettini, E. Spyropoulou, P. Poikonen-Saksela, P. Simos

Summary: This study examined the longitudinal impact of self-efficacy on coping with cancer and cancer-related coping reactions among breast cancer patients. The findings suggest that self-efficacy predicts coping reactions, and coping reactions also predict changes in self-efficacy. This relationship is complex and requires new theoretical models for a more accurate description.

PSYCHOLOGY & HEALTH (2023)

Add to Collection

Article Psychology, Clinical

The Interplay Between Trait Resilience and Coping Self-efficacy in Patients with Breast Cancer: An International Study

E. C. Karademas, P. Simos, R. Pat-Horenczyk, I Roziner, K. Mazzocco, B. Sousa, G. Stamatakos, G. Tsakou, F. Cardoso, D. Frasquilho, E. Kolokotroni, C. Marzorati, J. Mattson, A. J. Oliveira-Maia, K. Perakis, G. Pettini, L. Vehmanen, P. Poikonen-Saksela

Summary: This study examined the role of self-efficacy in coping with breast cancer as a mediator and/or moderator in the relationship between trait resilience and quality of life and psychological symptoms. The results showed that coping self-efficacy mediated the impact of trait resilience, and higher levels of resilience combined with higher levels of coping self-efficacy were associated with better outcomes.

JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS (2023)

Add to Collection

Article Oncology

International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients

K. M. de Ligt, B. H. de Rooij, E. Hedayati, M. M. Karsten, V. R. Smaardijk, M. Velting, C. Saunders, L. Travado, F. Cardoso, E. Lopez, N. Carney, Y. Wengstrom, A. Ives, G. Velikova, M. D. L. Sousa Fialho, Y. Seidler, T. A. Stamm, L. B. Koppert, L. V. van de Poll-franse

Summary: For patients living with metastatic breast cancer (MBC), it is crucial to achieve the best possible health-related quality of life and maximize survival. However, there is currently no systematic way to determine if these goals are being achieved. A Core Outcome Set (COS) that allows standardized measurement of outcomes important to patients and promotes discussion of these outcomes during clinical encounters is urgently needed.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar

Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Josephine M. N. L. Cardozo, Irene L. E. Andrulis, Stig E. Bojesen, Thilo M. Doerk, Diana M. A. Eccles, Peter A. J. Fasching, Maartje J. Hooning, Renske Keeman, Heli Nevanlinna, Emiel J. T. F. Rutgers, Douglas F. Easton, Per Hall, Paul D. P. J. Pharoah, Laura J. K. van't Veer, Marjanka K. Schmidt

Summary: A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. The results showed that PRS313 is associated with favorable tumor characteristics but not independently associated with prognosis. Rating: 8/10.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

In Honor of Hans-Jorg Senn

Beat Thurlimann, Alberto Costa, Fatima Cardoso

BREAST (2023)

Add to Collection

Article Oncology

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management

Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat

Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology

Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco, Shimere Sherwood

Summary: ASCO has taken steps to raise awareness about biosimilar products and published a statement in 2018 to provide guidance on their use in oncology. The FDA has approved a significant number of biosimilar products for use in the United States, including those for cancer treatment. The recent approval of interchangeable biosimilar products for various diseases has further expanded the market. This policy statement by ASCO proposes recommendations on value, interchangeability, clinician barriers, and patient education and access to guide their future activities.

JCO ONCOLOGY PRACTICE (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Changes over time in self-efficacy to cope with cancer and well-being in women with breast cancer: a cross-cultural study

E. C. Karademas, I. Roziner, P. Simos, K. Mazzocco, R. Pat-Horenczyk, B. Sousa, A. J. Oliveira-Maia, G. Stamatakos, F. Cardoso, E. Kolokotroni, R. Lemos, C. Marzorati, J. Mattson, Pettini Greta, L. Travado, P. Poikonen-Saksela

Summary: This study aimed to investigate the changes in self-efficacy to cope with cancer over time in breast cancer patients and whether these changes were similar across patients. It also aimed to explore the relationship between these trajectories and patient psychological well-being and overall quality of life. A total of 404 participants from four countries were assessed a few weeks after breast surgery or biopsy. The majority of patients reported high levels of self-efficacy to cope, which increased over time. However, about 15% of patients experienced a decline in self-efficacy over time, which was associated with worse levels of well-being. The patterns of self-efficacy changes and their relationships with well-being were consistent across the countries.

PSYCHOLOGY & HEALTH (2023)

Add to Collection

Article Medical Informatics

Aid of a machine learning algorithm can improve clinician predictions of patient quality of life during breast cancer treatments

Mikko Nuutinen, Anna-Maria Hiltunen, Sonja Korhonen, Ira Haavisto, Paula Poikonen-Saksela, Johanna Mattson, Georgios Manikis, Haridimos Kondylakis, Panagiotis Simos, Ketti Mazzocco, Ruth Pat-Horenczyk, Berta Sousa, Fatima Cardoso, Isabel Manica, Ian Kudel, Riikka-Leena Leskela

Summary: This study aimed to examine whether machine learning can improve the prediction accuracy of clinicians in assessing breast cancer patients' quality of life. The results showed that incorporating machine learning into the clinical decision support system significantly enhanced clinicians' ability to predict patients' QoL.

HEALTH AND TECHNOLOGY (2023)

Add to Collection

Correction Health Care Sciences & Services

Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study (vol 12, e37177, 2022)

Jelena Maksimenko, Pedro Pereira Rodrigues, Miki Nakazawa-Miklasevica, David Pinto, Edvins Miklasevics, Genadijs Trofimovics, Janis Gardovskis, Fatima Cardoso, Maria Joao Cardoso

JMIR FORMATIVE RESEARCH (2023)

Add to Collection

Article Oncology

European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care

Fatima Cardoso, Amelia McCartney, Antonio Ponti, Lorenza Marotti, Conny Vrieling, Alexandru Eniu, Berta Sousa, Carla Ripamonti, Luzia Travado, Sabine Spitz, Eva Jolly, Giuseppe Curigliano, Frederique Penault-Llorca, Frederic Lecouvet, Isabel T. Rubio, Laura Biganzoli

Summary: The European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance have developed the first set of quality indicators for metastatic breast cancer (MBC) with the aim of ensuring high-quality care and adherence to guidelines in breast cancer centers.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2-Advanced Breast Cancer: Findings From a Multicountry Survey

Fatima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter A. Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel, Eva Schumacher-Wulf

Summary: This article examines the perspectives of healthcare professionals and patients on quality of life (QOL) and the impact of treatment-related side effects on QOL. The study found discrepancies between healthcare professionals and patients regarding the importance of QOL discussions and the impact of side effects on QOL.

ONCOLOGIST (2023)

Add to Collection

Article Oncology

Augmented Reality in Breast Surgery Education

Pedro F. Gouveia, Rogelio Luna, Francisco Fontes, David Pinto, Carlos Mavioso, Joao Anacleto, Rafaela Timoteo, Joao Santinha, Tiago Marques, Fatima Cardoso, Maria Joao Cardoso

Summary: Augmented reality (AR) has the potential to benefit the healthcare sector through real-time data acquisition, machine learning-aided processing, and visualization. This paper focuses on the future use of AR in breast surgery education, specifically surgical telementoring and impalpable breast cancer localization. The success of these applications depends on improvements in data transformation and infrastructures. (c) 2023 S. Karger AG, Basel

BREAST CARE (2023)

Add to Collection

Article Oncology

Augmented Reality in Breast Surgery Education

Pedro Filipe Pereira Gouveia, Rogelio Luna, Francisco Fontes, David Pinto, Carlos Mavioso, Joao Anacleto, Rafaela Timoteo, Joao Santinha, Tiago Marques, Fatima Cardoso, Maria Joao Cardoso

Summary: Augmented Reality (AR) has the potential to bring numerous benefits and educational applications in the virtual health ecosystem. This paper focuses on the future applications of AR in breast surgery education, specifically discussing two potential use cases and the technical requirements to make them possible.

BREAST CARE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.